EP4491175A1 — A solid oral composition of ruxolitinib
Assigned to Genepharm SA · Expires 2025-01-15 · 1y expired
What this patent protects
A solid oral composition comprising (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile or its pharmaceutically acceptable salt and one or more pharmaceutically acceptable excipients; wherein 90% or more of the (R)-3-(4-(7H-pyrrolo [2,3-d]pyrim…
USPTO Abstract
A solid oral composition comprising (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile or its pharmaceutically acceptable salt and one or more pharmaceutically acceptable excipients; wherein 90% or more of the (R)-3-(4-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile is released within 30 minutes at pH 0.1 to 6.8 at 37.0°C ± 0.5°C using a USP II paddle apparatus at stirring speed of 50 rpm.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.